An international multicenter examination of MOG antibody assays
Journal article
WATERS P., (2019), Neurology, Neuroimmunology and Neuroinflammation
Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder.
Journal article
Yamamura T. et al, (2019), N Engl J Med, 381, 2114 - 2124
Congenital myasthenic syndrome due to mutations in MUSK suggests that the level of MuSK phosphorylation is crucial for governing synaptic structure.
Journal article
Rodríguez Cruz PM. et al, (2019), Hum Mutat
Classifying the antibody-negative NMO syndromes: Clinical, imaging, and metabolomic modeling.
Journal article
Yeo T. et al, (2019), Neurol Neuroimmunol Neuroinflamm, 6
The frequency of longitudinally extensive transverse myelitis in MS: A population-based study.
Journal article
Asnafi S. et al, (2019), Mult Scler Relat Disord, 37
β2-Adrenergic receptor agonists ameliorate the adverse effect of long-term pyridostigmine on neuromuscular junction structure.
Journal article
Vanhaesebrouck AE. et al, (2019), Brain
Clinically relevant cranio-caudal patterns of cervical cord atrophy evolution in MS.
Journal article
Rocca MA. et al, (2019), Neurology
Comparison of Clinical Outcomes of Transverse Myelitis Among Adults With Myelin Oligodendrocyte Glycoprotein Antibody vs Aquaporin-4 Antibody Disease.
Journal article
Mariano R. et al, (2019), JAMA Netw Open, 2
A large international aquaporin-4 antibody data set: combines individual factors to predict prognosis, identifies the risk of post-onset attack disability and calculates the power for future clinical trials
Conference paper
Nakashima I. et al, (2019), MULTIPLE SCLEROSIS JOURNAL, 25, 90 - 90
An international retrospective multi-center study of retinal optical coherence tomography in neuromyelitis optica spectrum disorders: the CROCTINO study
Conference paper
Oertel FC. et al, (2019), MULTIPLE SCLEROSIS JOURNAL, 25, 709 - 711
Causes of death in AQP4-IgG neuromyelitis optica spectrum disorder (NMOSD) in the United Kingdom NMOSD Service
Conference paper
Gibbons E. et al, (2019), MULTIPLE SCLEROSIS JOURNAL, 25, 588 - 589
Cervical cord atrophy in AQP4-Ab NMOSD, MOG-Ab disease & MS
Conference paper
Mariano R. et al, (2019), MULTIPLE SCLEROSIS JOURNAL, 25, 587 - 588
Combined omics analysis of cerebrospinal fluid is able to predict conversion from clinically isolated syndrome to clinically definite MS within 4 years
Conference paper
Probert F. et al, (2019), MULTIPLE SCLEROSIS JOURNAL, 25, 277 - 278
Diagnosis and staging of multiple sclerosis using a metabolomics-based blood test: a simple method for monitoring progression independently of EDSS
Conference paper
Probert F. et al, (2019), MULTIPLE SCLEROSIS JOURNAL, 25, 500 - 501
Impact of eculizumab on disability measures in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: phase 3 PREVENT study
Conference paper
Palace J. et al, (2019), MULTIPLE SCLEROSIS JOURNAL, 25, 737 - 738
Impact of eculizumab on hospitalization rates and relapse treatment in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: findings from the phase 3 PREVENT study
Conference paper
Kim HJ. et al, (2019), MULTIPLE SCLEROSIS JOURNAL, 25, 288 - 289
Impact of eculizumab on reported quality of life in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: findings from the PREVENT study
Conference paper
Berthele A. et al, (2019), MULTIPLE SCLEROSIS JOURNAL, 25, 294 - 295
Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial
Journal article
Cree BAC. et al, (2019), The Lancet
Influence of migration on the prognosis of neuromyelitis optica spectrum disorder in non-Caucasian patients
Conference paper
Soares dos Reis R. et al, (2019), MULTIPLE SCLEROSIS JOURNAL, 25, 138 - 139
Long-term safety and effectiveness of eculizumab in neuromyelitis optica spectrum disorder
Conference paper
Wingerchuk DM. et al, (2019), MULTIPLE SCLEROSIS JOURNAL, 25, 45 - 46